No data to show
XNAS
ACTU
Market cap112mUSD
Jul 18, Last price
5.76USD
1D
-7.99%
1Q
-28.00%
IPO
-37.05%
Name
Actuate Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-27m
CFO
-22m
Profile
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY |
|---|---|
| 2024‑12 | |
| Income | |
Revenues | |
Cost of revenue | 25,161 |
Unusual Expense (Income) | |
NOPBT | (25,161) |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | (25,161) |
Net income | (27,285) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | 24,442 |
BB yield | -36.67% |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | 412 |
Net debt | (8,642) |
| Cash flow | |
Cash from operating activities | (21,843) |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | 27,526 |
FCF | |
| Balance | |
Cash | 8,642 |
Long term investments | |
Excess cash | 8,642 |
Stockholders' equity | (132,380) |
Invested Capital | 132,896 |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | 8,373 |
Price | 7.96 |
Market cap | 66,647 |
EV | 58,005 |
EBITDA | (25,161) |
EV/EBITDA | |
Interest | 19 |
Interest/NOPBT | |